Magrolimab: all 25 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT05835011Phase 2Results posted
- Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)TerminatedNCT05330429Phase 2Results posted
- Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaTerminatedNCT05079230Phase 3Results posted
- Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell CarcinomaTerminatedNCT04854499Phase 2Results posted
- Study of Magrolimab in Patients With Solid TumorsTerminatedNCT04827576Phase 2Results posted
- Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin LymphomaTerminatedNCT04788043Phase 2Results posted
- Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedNCT04778397Phase 3Results posted
- Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell MalignanciesCompletedNCT04599634Phase 1Results posted
- Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to TreatmentTerminatedNCT04541017Phase 1/2Results posted
- Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaTerminatedNCT04435691Phase 1/2Results posted
- Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)TerminatedNCT04313881Phase 3Results posted
- A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaTerminatedNCT03922477Phase 1Results posted
- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
- Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum ChemotherapyCompletedNCT03558139Phase 1Results posted
- Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal CancerCompletedNCT02953782Phase 1/2Results posted
- An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic CancerActive, not recruitingNCT06532344Phase 1
- An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaWithdrawnNCT05929716Phase 2
- Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDSWithdrawnNCT05823480Phase 1
- Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsWithdrawnNCT05807126Phase 1
- Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial CarcinomaWithdrawnNCT05738161Phase 1
- Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain TumorsCompletedNCT05169944Phase 1
- ONO-7913 Phase I Study (ONO-7913)CompletedNCT04403308Phase 1
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
- CAMELLIA: Anti-CD47 Antibody Therapy in Haematological MalignanciesCompletedNCT02678338Phase 1
- Phase 1 Trial of Hu5F9-G4, a CD47-targeting AntibodyCompletedNCT02216409Phase 1